(lp0
S"The Reason Behind BioCryst Pharmaceuticals, Inc.'s 12% Pop Higher Motley Fool - Mar 8, 2017 Shares of BioCryst Pharmaceuticals , a biotech company that develops small-molecule drugs to block enzymes involved in disease proliferation, surged as much as 12% today after a report was issued that a highly pathogenic H5N1 bird flu&nbsp;...DE Shaw is Buying Biocryst Pharmaceuticals Inc.  Shares - Small Cap Exclusive "
p1
aS"Here's Why BioCryst Pharmaceuticals Inc. Catapulted Higher by as Much as 17% Motley Fool - Feb 28, 2017 Shares of BioCryst Pharmaceuticals , a biopharmaceutical company primarily focused on the development of small-molecule drugs that block enzymes associated with the development of diseases, catapulted higher by as much as 17%&nbsp;..."
p2
aS"Insider Trading Activity BioCryst Pharmaceuticals, Inc.   CFO ... Market Exclusive - 12 hours ago Thomas R Staab II , CFO of BioCryst Pharmaceuticals, Inc.  reportedly Sold 3,250 shares of the company's stock at an average price of 9.2 for a total transaction amount of $29,900.00 SEC Form.Revenue Approximations Analysis: BioCryst Pharmaceuticals, Inc. , xG ... - StockNewsJournalWhat Analysts are Predicting For BioCryst Pharmaceuticals, Inc. (BCRX ... - The USA Commerce"
p3
aS'BioCryst Pharmaceuticals Inc.  Plunges 9.89% on March 21 Equities.com - Mar 21, 2017 BioCryst Pharmaceuticals Inc.  had a rough trading day for Tuesday March 21 as shares tumbled 9.89%, or a loss of $-0.91 per share, to close at $8.29.'
p4
aS'BioCryst Pharmaceuticals Inc.  Breaks into New 52-Week High on March 21 ... Equities.com - Mar 21, 2017 Shares of BioCryst Pharmaceuticals Inc.  broke into a new 52-week high yesterday, hitting a peak of $9.25. Shares closed at $8.29 after opening at $9.25 for a move of -9.89%.'
p5
aS'BioCryst Pharmaceuticals Inc.  Breaks into New 52-Week High on March 20 ... Equities.com - Mar 20, 2017 Shares of BioCryst Pharmaceuticals Inc.  broke into a new 52-week high yesterday, hitting a peak of $9.21. Shares closed at $9.20 after opening at $8.82 for a move of 3.95%.'
p6
aS'Analyst Recommendations on These Shares: BioCryst Pharmaceuticals, Inc ... Sherwood Daily - 16 hours ago Brokerage firms currently have a positive stance on shares of BioCryst Pharmaceuticals, Inc. . The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 2.30.'
p7
aS'BioCryst Pharmaceuticals, Inc.  Files An 8-K Entry into a ... Market Exclusive - Mar 17, 2017 BioCryst Pharmaceuticals, Inc.  is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases.BioCryst Pharmaceuticals, Inc.  Makes The Move To Publicize Its ... - Journal TranscriptInvestors Focused Stock: BioCryst Pharmaceuticals, Inc.  - Is stories'
p8
aS'Option Trading: BioCryst Pharmaceuticals Inc  Long Put Spreads ... CML News - 19 hours ago As we look at BioCryst Pharmaceuticals Inc we note that a long put spread is one of the most common implementations of an option strategy during a bull market, but the analysis completed when employing the long put spread often times lacks the ...'
p9
aS'BioCryst Pharmaceuticals, Inc.  Bearish Target At $11 Stock Observer - Mar 21, 2017 Zacks Research ABR on BioCryst Pharmaceuticals, Inc.  is 1.78. Average brokerage rating notes the stock ratings of research groups in the industry.'
p10
a.